Wave Life Sciences
Yahoo Finance • 11 months ago
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastatin... Full story
Yahoo Finance • 11 months ago
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences USA, Inc. WVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manif... Full story
Yahoo Finance • 11 months ago
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced... Full story
Yahoo Finance • 12 months ago
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs;dosing on track for 4Q 2023 andfirst-in-human proof-of-mechanism data anticipated in 2024 On track to de... Full story
Yahoo Finance • last year
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live... Full story
Yahoo Finance • last year
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK WVE-006 –... Full story
Yahoo Finance • last year
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced... Full story
Yahoo Finance • last year
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced... Full story
Yahoo Finance • last year
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby... Full story
Yahoo Finance • last year
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced t... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA editing and advanced WVE-006 for AATD – first... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced t... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced to... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced to... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced to... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using an oligonucleotide to harness an endog... Full story
Yahoo Finance • 2 years ago
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced to... Full story
